Idiosyncratic drug hepatotoxicity: A 2008 update

Expert Review of Clinical Pharmacology

Volumn 1, Issue 2, 2008, Pages 261-276

  Andrade, Raúl J ^a   Ortega López, Susana ^a   López Vega, Ma Carmen ^a   Robles, Mercedes ^a   Cueto, Ignacio ^a   Lucena, Ma Isabel ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

Causality assessment; Chronic DILI; Determinant of prognosis; Drug induced liver injury

Indexed keywords

ACETYLCYSTEINE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BETAHISTINE; CARBAMAZEPINE; CARNITINE; CEFALEXIN; CHLORPROMAZINE; CORTICOSTEROID; COTRIMOXAZOLE; DICLOFENAC; ERYTHROMYCIN; FLUCLOXACILLIN; ISONIAZID; METOCLOPRAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYTETRACYCLINE; PARACETAMOL; PLACEBO; SALAZOSULFAPYRIDINE; STOMACH SECRETION INHIBITOR; TICLOPIDINE; TRIMETHOPRIM; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VITAMIN;

AGE; ALCOHOL CONSUMPTION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL DECISION MAKING; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DRUG METABOLISM; DRUG OVERDOSE; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; GENDER; GENETIC RISK; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOGENESIS; INCIDENCE; LABORATORY TEST; LIVER BIOPSY; LIVER FAILURE; LIVER TOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PHARMACOGENETICS; POPULATION RESEARCH; PRESCRIPTION; PREVALENCE; PROGNOSIS; RATING SCALE; RELIABILITY; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; STANDARDIZATION;

EID: 49249109082     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/17512433.1.2.261     Document Type: Review

References (112)

1. 2-receptor antagonist. J. Hepatol. 31, 641-646 (1999).
2. Herrine SK, Choudary C. Severe hepatotoxicity associated with troglitazone. Ann. Intern. Med. 130, 163-164 (1999).
3. Lucena MI, Andrade RJ, Rodrigo L et al. Trovafloxacin-induced acute hepatitis. Clin. Infect. Dis. 30, 400-401 (2000).
4. Lee WM, Larrey D, Olsson R et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf. 28, 351-370 (2005).
5. Clay KC, Hanson JS, Pope SD, Rissmiller RW, Purdum III PP, Banks PD. Severe hepatotoxicity of telithromycin: three case reports and literature review. Ann. Intern. Med. 144, 415-420 (2006).
6. Benninger J, Schneider HT, Schuppan D, Kirchner T, Hahn EG. Acute hepatitis induced by greater celandine (Chelidonium majus). Gastroenterology 117, 1234-1237 (1999).
7. Stickël F, Baumuller HM, Seitz KH et al. Hepatitis induced by kava (Piper methysticum rhizoma). J. Hepatol. 9, 62-67 (2003).
8. Adachi M, Saito H, Kobayashi H et al. Hepatic injury in 12 patients taking the herbal weight loss aids Chaso or onshido. Ann. Intern. Med. 139, 488-492 (2003).
9. Neff GW, Reddy KR, Durazo FA, Meyer D, Marrero R, Kaplowitz N. Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. J. Hepatol. 41, 1062-1064 (2004).
10. Bonkovsky HL. Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann. Intern. Med. 144, 68-71 (2006).
11. Schoepfer AM, Engel A, Fattinger K et al. Herbal does not mean innocuous: 10 cases of severe hepatotoxicity associated with dietary supplements from Herbalife® products. J. Hepatol. 47, 521-526 (2007).
12. Elinav E, Pinsker G, Safadi R et al. Association between consumption of Herbalife® nutritional supplements and acute hepatotoxicity. J. Hepatol. 47, 514-520 (2007).
13. Ostapowicz G, Fontana RJ, Schiødt FV et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. 137, 947-954 (2002).
14. Hoofnagle JH. Drug-induced liver injury network (DILIN). Hepatology 40, 773 (2004).
15. Andrade RJ, Lucena MI, Fernández MC et al. Drug- induced liver injury: an analysis of 461 incidences submitted to the Spanish Registry over a 10-year period. Gastroenterology 129, 512-521 (2005).
16. Almdal TP, Sorensen TI. Incidence of parenchymal liver diseases in Denmark, 1981 to 1985: analysis of hospitalization registry data. The Danish Association for the Study of the Liver. Hepatology 13, 650-655 (1991).
17. Garcia Rodriguez LA, Perez Gutthann S, Walker AM, Lueck L. The role of non-steroidal anti-inflammatory drugs in acute liver injury. Br. Med. J. 305, 865-868 (1992).
18. Perez Gutthann S, Garcia Rodriguez LA. The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs. Epidemiology 4, 496-501 (1993).
19. Carson JL, Strom BL, Duff A et al. Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines. Ann. Intern. Med. 119, 576-583 (1993).
20. Byron D, Minuk GY. Clinical hepatology: profile of an urban, hospital-based practice. Hepatology 24, 813-815 (1996).
21. Garcia Rodriguez LA, Ruigomez A, Jick H. A review of epidemiologic research on drug-induced acute liver injury using the general practice research data base in the United Kingdom. Pharmacotherapy 17, 721-728 (1997).
22. Duh MS, Walker AM, Kronlund KH Jr. Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts. Pharmacoepidemiol. Drug Saf. 8, 275-283 (1999).
23. Galan MV, Potts JA, Silverman AL, Gordon SC. Hepatitis in a United States tertiary referral center. J. Clin. Gastroenterol. 39, 64-67 (2005).
24. Farrell OC. Drug-induced Liver Disease. Churchill Livingstone, London, UK (1994).
25. Friis H, Andreasen PB. Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. J. Intern. Med. 232, 133-138 (1992).
26. Pillans PI. Drug-associated hepatic reactions in New Zealand: 21 years experience. NZ Med. J. 109, 315-319 (1996).
27. Björnsson E, Jerlstad P, Bergquist A, Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand. J. Gastroenterol. 40, 1095-1101 (2005).
28. Sgro C, Clinard F, Ouazir K et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 36, 451-455 (2002).
29. Whitehead MW, Hainsworth I, Kingham JGC. The causes of obvious jaundice in South West Wales: 2000. Gut 48, 409-413 (2001).
30. Björnsson E, Ismael S, Nejdet S, Kilander A. Severe jaundice in Sweden in the new millennium: causes, investigations, treatment and prognosis. Scand. J. Gastroenterol. 38, 86-94 (2003).
31. Vuppalanchi R, Liangpunsakul S, Chalasani N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States? Am. J. Gastroenterol. 102, 558-556 (2007).
32. Whitehead MW, Hawkes ND, Hainsworth I, Kingham JGC. A prospective study of the causes of notably raised aspartate aminotransferase of liver origin. Gut 45, 129-133 (1999).
33. Bagheri H, Michel F, Lapeyre-Mestre M et al. Detection and incidence of drug-induced liver injuries in hospital: a prospective analysis from laboratory signals. Br. J. Clin. Pharmacol. 50, 479-484 (2000).
34. Meier Y, Cavallaro M, Roos M et al. Incidence of drug-induced liver injury in medical inpatients. Eur. J. Clin. Pharmacol. 61, 135-143 (2005).
35. Ibáñez L, Pérez E, Vidal X, Laporte JR, the Grup d'Estudi Multicentric d'Hepatotoxicitat Aguda de Barcelona (GEMHAB). Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J. Hepatol. 37, 592-600 (2002).
36. Hussaini SH, O'Brien CS, Despott EJ, Dalton HR. Antibiotic therapy: a major cause of drug-induced jaundice in southwest England. Eur. J. Gastroenterol. Hepatol. 19, 15-20 (2007).
37. De Abajo FJ, Montero D, Madurga M, Garcia Rodriguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br. J. Clin. Pharmacol. 58, 71-80 (2004).
38. Chalasani N, Fontana R, Watkins PB et al. Drug-induced liver injury network (DILIN). Prospective study: initial results. Am. J. Gastroenterol. 101, S168 (2006).
39. Boelsterli UA, Lim PLK. Mitochondrial abnormalities. A link to idiosyncratic drug hepatotoxicity? Toxicol. Appl. Pharmacol. 220 92-107 (2007).
40. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 4, 489-499 (2005).
41. Walgren JL, Mitchell MD, Thompson DC. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxicol. 35, 325-361 (2005).
42. Pessayre D. Role of reactive metabolites in drug-induced hepatitis. J. Hepatol. 23 (1 Suppl.), 16-24 (1995).
43. Robin MA, Le Roy M, Descatoire V, Pessayre D. Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J. Hepatol. 26(1 Suppl.), 23-30 (1997).
44. Berson A, De Beco V, Letteron P et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 114, 764-774 (1998).
45. Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis. Semin. Liver Dis. 21, 57-69 (2001).
46. Pessayre D, Haouzi D, Fau D, Robin MA, Mansouri A, Berson A. Withdrawal of life support, altruistic suicide, fratricidal killing and euthanasia by lymphocytes: different forms of drug-induced hepatic apoptosis. J. Hepatol. 31(4), 760-770 (1999).
47. Liu ZX, Govindarajan S, Kaplowitz N. Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology 127, 1760-1774 (2004).
48. Lucena MI, Carvajal A, Andrade RJ, Velasco A. Antidepressant-induced hepatotoxicity. Expert Opin. Drug Saf. 2, 249-262 (2003).
49. Andrade RJ, Lucena MI, Alcantara R, Fraile JM. Bentazepam-associated chronic liver disease. Lancet 343, 860 (1994).
50. Kaplowitz N. Liver biology and pathobiology. Hepatology 43(Suppl. 1), S235-S238 (2006).
51. Garcia Rodriguez LA, Stricker BH, Zimmermann HI. Risk of acute liver injury associated with the combination of amoxicllin and clavulanic acid. Arch. Intern. Med. 156, 1327-1332 (1996).
52. Fountain FF, Tolley E, Chrisman CR, Self TH. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 128, 116-123 (2005).
53. Kaplowitz N, Deleve LD. Drug-induced Liver Disease (2nd Edition). Informa-Healthcare, NY, USA (2007).
54. Pauli-Magnus C, Meier PJ. Hepatobiliary transporters and drug-induced cholestasis. Hepatology 4, 778-787 (2006).
55. Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 10, 1018-1023 (2004).
56. Zimmerman HJ. Hepatotoxicity: the Adverse Effects of Drugs and Other Chemicals on the Liver (2nd Edition). Lippincott Williams & Wilkins, PA USA (1999).
57. Bonfanti P, Landonio S, Ricci E et al. Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 27, 316-318 (2001).
58. Rosenberg P, Urwitz H, Johansson A et al. Psoriasis patients with diabetes mellitus type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J. Hepatol. 46, 1111-1118 (2007).
59. Russo WM, Watkins PB. Are patients with elevated liver tests at increased risk of drug-induced liver injury? Gastroenterology 126, 1477-1480 (2004).
60. Lewis JH. The rational use of potentially hepatotoxic medications in patients with underlying liver disease. Expert Opin. Drug Saf. 1, 159-172 (2002).
61. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 126, 1287-1292 (2004).
62. Morgan MY, Reshef R, Shah RR, Oates NS, Smith RL, Sherlock S. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 25, 1057-1064 (1984).
63. Alvan G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur. J. Clin. Pharmacol. 39, 533-537 (1990).
64. Horsmans Y, Lannes D, Pessayre D, Larrey D. Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium, a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate. J. Hepatol. 21, 1075-1079 (1994).
65. Pachkoria K, Lucena MI, Ruiz-Cabello F, Crespo E, Cabello MR, Andrade RJ. Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury. Br. J. Pharmacol. 150, 808-815 (2007).
66. Huang YS, Chern HD, Su WJ et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 37, 924-930 (2003).
67. Huang YS, Su WJ, Huang YH et al. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H: quinone oxidoreductase, glutathione S-transferase M1 and T1 and the susceptibility to drug-induced liver injury. J. Hepatol. 47, 128-134 (2007).
68. Simon T, Becquemont L, Mary-Krause M et al. Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin. Pharmacol. Ther. 67, 432-437 (2000).
69. Watanabe I, Tomita A, Shimizu M et al. A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin. Pharmacol. Ther. 73, 435-455 (2003).
70. Taniguchi A, Urano W, Tanaka E et al. Validation of the association between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice. Pharmacogenet. Genomics 17, 383-390 (2007).
71. Daly AK, Aithal GP, Leathart JBS, Swainsbury RA, Dang TS, Day CP. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 132, 272-281 (2007).
72. Aithal GP, Ramsay L, Daly AK et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 39, 1430-1440 (2004).
73. Pachkoria K, Crespo E, Ruiz-Cabello F et al. Genetic polymorphisms of IL- 10, IL-4 and TNF α and susceptibility to develop drug-induced idiosyncratic liver injury (DILI). Hepatology 46(Suppl.), 809A (2007).
74. Andrade RJ, Lucena MI, Alonso A et al. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology 39, 1603-1612 (2004).
75. Kindmark A, Jawaid A, Harbron CG et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. DOI: 10.1038/sj.tpj.6500458 (2007) (Epub ahead of print).
76. Benichou C. Criteria of drug-induced liver disorders. Report of an International Consensus Meeting. J. Hepatol. 11, 272-276 (1990).
77. Larrey D. Drug-induced liver diseases. J. Hepatol. 32(Suppi. 1), 77-88 (2000).]
78. Goodman ZD. Drug hepatotoxicity. Clin. Liver Dis. 6, 381-397 (2002).
79. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N. Engl. J. Med. 354, 731-739 (2006).
80. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 42, 481-489 (2005).
81. Björnsson E, Nordlinder H, Olsson R. Clinical characteristics and prognostic markers in disulfiram-induced liver injury. J. Hepatol. 44, 791-797 (2006).
82. Björnsson E, Kalaitzakis E, Olsson R. The impact of cosinophilia. and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment. Pharmacol. Ther. 25, 1411-1421 (2007).
83. Watkins PB. Idiosyncratic liver injury. challenges and approaches. Toxicol. Pathol. 33, 1-5 (2005).
84. Lucena MI, Andrade RJ, Fernandez MC et al. Determinants ofthe clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology 44, 850-856 (2006).
85. Andrade RJ, Lucena MI, Kaplowitz N et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology 44, 1581-1588 (2006).
86. Björnsson, E, Kalaitzakis E, Klinteberg VAV, Alem N, Olsson R. Long-term fOllOW-Up in patients with mild to moderate drug-induced liver injury. Aliment. Pharmacol. Ther. 26, 79-85 (2007).
87. Aithal GP, Rawlins MD, Day CP. Accuracy of hepatic adverse drug reaction reporting in one English health region. Br. Med. J. 319, 1541 (1999).
88. Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf. 24, 483-490 (2001).
89. Andrade RJ, Robles M, Fernandez-Castañer A, Lṕez-Ortega S, López-Vega MC, Lucena. MI. Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J. Gastroenterol. 13, 329-340 (2007).
90. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 33, 308-310 (2001).
91. Lee WM, Senior JR. Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol. Pathol. 33, 155-164 (2005).
92. Andrade RJ, Camargo R, Lucena MI, González-Grande R. Causality assessment in drug-induced hepatotoxicity. Expert Opin. Drug Saf. 3, 329-344 (2004).
93. Bianchi L. Liver biopsy in elevated liver function tests? An old question revisited. J. Hepatol. 35, 290-294 (2001).
94. Andrade RJ, Lucena MI, Aguilar J et al. Chronic liver injury related with the use of bentazepam: an unusual instance of benzodiazepine hepatotoxicity. Dig. Dis. Sci. 45, 1400-1404 (2000).
95. Degott C, Feldmann G, Larrey D et al. Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology 15, 244-251(1992).
96. Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut 44, 731-735 (1999).
97. Lucena MI, Andrade RJ, Camargo R, García-Cortés M. Causality assessment. In: Drug-Induced Liver Disease (2nd Edition). Kaplowitz N, DeLeeve L (Eds). Informa-Healthcare, NY, USA 325-344 (2007).
98. Danan G, Bénichou C. Causality assessment of adverse reactions to drugs I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J. Clin. Epidemiol. 46, 1323-1330. (1993).
99. Maria V, Victorino R. Development and validation of a clinical scale for the diagnosis ofdrug-induced hepatitis. Hepatology 26, 664-669 (1997).
100. Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, Sáchez De La Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 33, 123-130 (2001).
101. Naranjo CA,.Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 30, 239-245 (1981).
102. Garcia-Cort-aces M, Pachkoria K, Lucena MI et al. Comparison of two clinical scales in the causality assessment of drug induced liver disease. J. Hepatol. 44(Suppl. 2), S253 (2006).
103. Lee WM. Assessing causality in drug-induced liver injury. J. Hepatol. 33, 1003-1005 (2000).
104. Rochon J, Seeff LB, Fontana RJ et al. A prospective study of the reliability of the RUCAM for assessing causality in drug-induced liver injury. Hepatology 46(Suppl. 1), 811A (2007).
105. Takikawa H, Takamori Y, Kumagi T et al. Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the International Consensus Meeting. Hepatol. Res. 27, 192-195 (2003).
106. Watanabe M, Shibuya A. Validity study of a new diagnostic scale for drug-induced liver injury in Japan-comparison with two previous scales. Hepatol. Res. 30, 148-154 (2004).
107. Makin AJ, Wendon J, Williams R. A 7-year experience of severe acetaminophen-induced hepatotoxicity (1987-1993). Gastroenterology 109, 1907-1916 (1995).
108. Lee WM, Rossaro L, Fontana RJ et al. Intravenous N-acetylcysteine improves spontaneous survival in early stage non-acetaminiphen acute liver failure. Hepatology 46(Suppl. 1), 268A (2007).
109. Bohan TP, Helton E, McDonald I et al. Effect of L-carnitine treatment for valproate induced hepatotoxicity. Neurology 56, 1405-1409 (2001).
110. Rakela J, Mosley JW, Edwards VM, Govindarajan S, Alpert E. A double-blinded, randomized trial of hydrocortisone in acute hepatic failure. The acute hepatic failure study group. Dig. Dis. Sci. 36, 1223-1228 (1991).
111. Spagnuolo MI, Iorio R, Vegnente A, Guarino A. Ursodeoxycholic acid for treatment of cholestasis in children on long-term total parenteral nutrition: a pilot study. Gastroenterology 111, 716-719 (1996).
112. Huster D, Schubert C, Bess F, Mossner J, Caca K. Rofecoxib-induced cholestatic hepatitis: treatment with molecular adsorbent recycling system (MARS). J. Hepatol. 37, 413-414 (2002).